b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="plosone" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2817000/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817000/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="PLoS ONE" /><meta name="citation_title" content="New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets" /><meta name="citation_authors" content="Robert H. E. Friesen, Wouter Koudstaal, Martin H. Koldijk, Gerrit Jan Weverling, Just P. J. Brakenhoff, Peter J. Lenting, Koert J. Stittelaar, Albert D. M. E. Osterhaus, Ronald Kompier, Jaap Goudsmit" /><meta name="citation_date" content="2010" /><meta name="citation_issue" content="2" /><meta name="citation_volume" content="5" /><meta name="citation_doi" content="10.1371/journal.pone.0009106" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2817000/?report=abstract" /><meta name="citation_pmid" content="20161706" /><meta name="DC.Title" content="New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Public Library of Science" /><meta name="DC.Contributor" content="Robert H. E. Friesen" /><meta name="DC.Contributor" content="Wouter Koudstaal" /><meta name="DC.Contributor" content="Martin H. Koldijk" /><meta name="DC.Contributor" content="Gerrit Jan Weverling" /><meta name="DC.Contributor" content="Just P. J. Brakenhoff" /><meta name="DC.Contributor" content="Peter J. Lenting" /><meta name="DC.Contributor" content="Koert J. Stittelaar" /><meta name="DC.Contributor" content="Albert D. M. E. Osterhaus" /><meta name="DC.Contributor" content="Ronald Kompier" /><meta name="DC.Contributor" content="Jaap Goudsmit" /><meta name="DC.Date" content="2010" /><meta name="DC.Identifier" content="10.1371/journal.pone.0009106" /><meta name="DC.Language" content="en" /><meta property="og:title" content="New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets" /><meta property="og:type" content="article" /><meta property="og:description" content="The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817000/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-plosone.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2817000/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2817000/pdf/pone.0009106.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1AD382E9A333C10000000008CB08CA.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/440/">PLoS One</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/184463/">v.5(2); 2010</a></li><li class="accid">PMC2817000</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-plosone.gif" alt="Logo of plosone" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,438,55" alt="PLoS One" title="PLoS One" href="http://www.plosone.org/" ref="reftype=publisher&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="0,56,104,74" alt="View this Article" title="View this Article" href="//dx.doi.org/10.1371/journal.pone.0009106" ref="reftype=publisher&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Content%20Provider%7CArticle%7CFullText" target="pmc_ext" /><area shape="rect" coords="106,56,202,74" alt="Submit to PLoS" title="Submit to PLoS" href="http://www.plosone.org/static/checklist.action" ref="reftype=publisher&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="204,56,302,74" alt="Get E-mail Alerts" title="Get E-mail Alerts" href="http://journals.plos.org/alerts" ref="reftype=publisher&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="304,56,374,74" alt="Contact Us" title="Contact Us" href="http://www.plosone.org/static/contact.action" ref="reftype=publisher&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="440,0,500,55" alt="Public Library of Science (PLoS)" title="Public Library of Science (PLoS)" href="http://www.plos.org/" ref="reftype=publisher&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">PLoS One</span>. 2010; 5(2): e9106. </span></div><div><span class="fm-vol-iss-date">Published online 2010 Feb 8. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1371%2Fjournal.pone.0009106" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1371/journal.pone.0009106</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2817000</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/20161706">20161706</a></div></div></div></div><h1 class="content-title">New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Friesen%20RH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833165140320" co-class="co-affbox">Robert H. E. Friesen</a>,<sup>\n1\n,</sup><sup>\n&#x0002a;\n</sup> <a href="/pubmed/?term=Koudstaal%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833165138336" co-class="co-affbox">Wouter Koudstaal</a>,<sup>\n1\n</sup> <a href="/pubmed/?term=Koldijk%20MH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833165136304" co-class="co-affbox">Martin H. Koldijk</a>,<sup>\n1\n</sup> <a href="/pubmed/?term=Weverling%20GJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833156711808" co-class="co-affbox">Gerrit Jan Weverling</a>,<sup>\n1\n</sup> <a href="/pubmed/?term=Brakenhoff%20JP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833156709440" co-class="co-affbox">Just P. J. Brakenhoff</a>,<sup>\n1\n</sup> <a href="/pubmed/?term=Lenting%20PJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833158887552" co-class="co-affbox">Peter J. Lenting</a>,<sup>\n1\n</sup> <a href="/pubmed/?term=Stittelaar%20KJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833158885184" co-class="co-affbox">Koert J. Stittelaar</a>,<sup>\n2\n</sup> <a href="/pubmed/?term=Osterhaus%20AD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833166139648" co-class="co-affbox">Albert D. M. E. Osterhaus</a>,<sup>\n2\n,</sup><sup>\n3\n</sup> <a href="/pubmed/?term=Kompier%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833165394144" co-class="co-affbox">Ronald Kompier</a>,<sup>\n1\n</sup> and  <a href="/pubmed/?term=Goudsmit%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706" class="affpopup" co-rid="_co_idm139833165391776" co-class="co-affbox">Jaap Goudsmit</a><sup>\n1\n</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139833165140320"><h3 class="no_margin">Robert H. E. Friesen</h3><p>  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Friesen%20RH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Robert H. E. Friesen</a></div></div><div id="_co_idm139833165138336"><h3 class="no_margin">Wouter Koudstaal</h3><p>  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Koudstaal%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Wouter Koudstaal</a></div></div><div id="_co_idm139833165136304"><h3 class="no_margin">Martin H. Koldijk</h3><p>  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Koldijk%20MH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Martin H. Koldijk</a></div></div><div id="_co_idm139833156711808"><h3 class="no_margin">Gerrit Jan Weverling</h3><p>  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Weverling%20GJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Gerrit Jan Weverling</a></div></div><div id="_co_idm139833156709440"><h3 class="no_margin">Just P. J. Brakenhoff</h3><p>  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Brakenhoff%20JP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Just P. J. Brakenhoff</a></div></div><div id="_co_idm139833158887552"><h3 class="no_margin">Peter J. Lenting</h3><p>  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Lenting%20PJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Peter J. Lenting</a></div></div><div id="_co_idm139833158885184"><h3 class="no_margin">Koert J. Stittelaar</h3><p>  <sup>2</sup>  ViroClinics BV, Rotterdam, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Stittelaar%20KJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Koert J. Stittelaar</a></div></div><div id="_co_idm139833166139648"><h3 class="no_margin">Albert D. M. E. Osterhaus</h3><p>  <sup>2</sup>  ViroClinics BV, Rotterdam, The Netherlands,   </p><p>  <sup>3</sup>  Department of Virology, Erasmus MC, Rotterdam, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Osterhaus%20AD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Albert D. M. E. Osterhaus</a></div></div><div id="_co_idm139833165394144"><h3 class="no_margin">Ronald Kompier</h3><p>  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Kompier%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Ronald Kompier</a></div></div><div id="_co_idm139833165391776"><h3 class="no_margin">Jaap Goudsmit</h3><p>  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </p><div>Find articles by <a href="/pubmed/?term=Goudsmit%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20161706">Jaap Goudsmit</a></div></div></div></div><div class="contrib-group half_rhythm fm-editor">Linqi Zhang, <span class="fm-role">Editor</span><sup></sup></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139833157632688_ai idm139833165140448_ai idm139833156912416_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139833157632688_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139833157632688_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139833157632688_ai" style="display:none"><div class="fm-affl" lang="en" id="aff1">  <sup>1</sup>  Crucell Holland BV, Leiden, The Netherlands,   </div><div class="fm-affl" lang="en" id="aff2">  <sup>2</sup>  ViroClinics BV, Rotterdam, The Netherlands,   </div><div class="fm-affl" lang="en" id="aff3">  <sup>3</sup>  Department of Virology, Erasmus MC, Rotterdam, The Netherlands,   </div><div class="fm-affl" lang="en" id="edit1">Tsinghua University, China</div><div id="cor1">&#x0002a; E-mail: <a href="mailto:dev@null" data-email="moc.llecurc@neseirf.trebor" class="oemail">moc.llecurc@neseirf.trebor</a></div><div><p id="__p1" class="p p-first-last">Conceived and designed the experiments: RHEF WK GJW PJL RK JG. Performed the experiments: KJS. Analyzed the data: MHK GJW JPJB ADMEO RK. Contributed reagents/materials/analysis tools: JPJB ADMEO. Wrote the paper: RHEF WK JG.</p></div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139833157632688_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2009 Jun 24; Accepted 2010 Jan 21.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139833157632688_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> Friesen et al.</div><div class="license half_rhythm">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2817000/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm139833163914384" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139833163914384title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Background</h3><p id="__p2" class="p p-first-last">The urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1 influenza pandemic. A recently discovered class of human monoclonal antibodies with the ability to neutralize a broad spectrum of influenza viruses (including H1, H2, H5, H6 and H9 subtypes) has the potential to prevent and treat influenza in humans. Here we report the latest efficacy data for a representative antibody of this novel class.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Methodology/Principal Findings</h3><p id="__p3" class="p p-first-last">We evaluated the prophylactic and therapeutic efficacy of the human monoclonal antibody CR6261 against lethal challenge with the highly pathogenic avian H5N1 virus in ferrets, the optimal model of human influenza infection. Survival rates, clinically relevant disease signs such as changes in body weight and temperature, virus replication in lungs and upper respiratory tract, as well as macro- and microscopic pathology were investigated. Prophylactic administration of 30 and 10 mg/kg CR6261 prior to viral challenge completely prevented mortality, weight loss and reduced the amount of infectious virus in the lungs by more than 99.9&#x00025;, abolished shedding of virus in pharyngeal secretions and largely prevented H5N1-induced lung pathology. When administered therapeutically 1 day after challenge, 30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and temperature rise, reduced lung viral loads and shedding, and less lung damage.</p></div><div id="__sec3" class="sec sec-last"><h3 id="__sec3title">Conclusions/Significance</h3><p id="__p4" class="p p-first-last">These data demonstrate the prophylactic and therapeutic efficacy of this new class of human monoclonal antibodies in a highly stringent and clinically relevant animal model of influenza and justify clinical development of this approach as intervention for both seasonal and pandemic influenza.</p></div></div></div><div id="s1" class="tsec sec"><h2 class="head no_bottom_margin" id="s1title">Introduction</h2><p id="__p5" class="p p-first">A novel class of human monoclonal antibodies against influenza has been recently discovered <a href="#pone.0009106-Throsby1" rid="pone.0009106-Throsby1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177852">[1]</a>. These antibodies bind to the membrane-proximal stem of haemagglutinin, the major viral surface protein, and neutralize the influenza virus by blocking its fusion with the host cell <a href="#pone.0009106-Ekiert1" rid="pone.0009106-Ekiert1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_674951253">[2]</a>. A panel of antibodies with a similar mode of action was reported subsequently by Sui <em>et al</em>. <a href="#pone.0009106-Sui1" rid="pone.0009106-Sui1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177880">[3]</a>. Due to the high conservation of their recognition site, this class of antibodies has shown the ability to neutralize a broad spectrum of influenza subtypes, including H1, H2, H5, H6 and H9 <a href="#pone.0009106-Throsby1" rid="pone.0009106-Throsby1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177862">[1]</a>, and can be expected to also neutralize viruses from subtypes H4, H8, H11&#x02013;H14 and H16, as well as their future antigenic drift variants <a href="#pone.0009106-Ekiert1" rid="pone.0009106-Ekiert1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_674951255">[2]</a>. One of these antibodies, CR6261, was investigated in mice and shown to be protective when given before and after lethal challenges with H1N1 and H5N1 virus, suggesting that it has potential as the first-ever broad-spectrum monoclonal antibody for prophylaxis and treatment of influenza virus infections <a href="#pone.0009106-Throsby1" rid="pone.0009106-Throsby1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177853">[1]</a>.</p><p id="__p6">According to the World Health Organization, seasonal influenza causes up to 500,000 deaths worldwide each year <a href="#pone.0009106-WHO1" rid="pone.0009106-WHO1" class=" bibr popnode">[4]</a>. Immunologically na&#x000ef;ve infants, immunocompromised individuals and the elderly are particularly susceptible to illness caused by seasonal influenza viruses, with 90&#x00025; of deaths occurring in the latter group <a href="#pone.0009106-WHO1" rid="pone.0009106-WHO1" class=" bibr popnode">[4]</a>, <a href="#pone.0009106-Hoelscher1" rid="pone.0009106-Hoelscher1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177857">[5]</a>. In addition, subtypes of influenza A viruses that have not previously circulated among humans occasionally cross from animal reservoirs, raising the spectre of a pandemic.</p><p id="__p7">Over the past decade, the most prominent pandemic threat appeared to be posed by highly pathogenic avian influenza viruses of subtype H5N1. However, it was a new strain of human H1N1 that emerged in Mexico and the United States in March and April 2009 and rapidly spread across the globe that caused the WHO to declare a pandemic on June 11th <a href="#pone.0009106-CDC1" rid="pone.0009106-CDC1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177868">[6]</a>, <a href="#pone.0009106-WHO2" rid="pone.0009106-WHO2" class=" bibr popnode">[7]</a>. Although the virulence of this virus is currently moderate, particularly compared to the case fatality rate of over 60&#x00025; of human H5N1 infections, this may change over time. Meanwhile, the threat from highly pathogenic avian H5N1 viruses persists as they continue to circulate and evolve in bird populations.</p><p id="__p8">Preventive vaccination has historically been the primary means of influenza control, but this approach has important limitations. Vaccines typically elicit a potent neutralizing antibody response only to the specific viral strains they contain, and closely related viruses <a href="#pone.0009106-Salzberg1" rid="pone.0009106-Salzberg1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177874">[8]</a>, <a href="#pone.0009106-CDC2" rid="pone.0009106-CDC2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177881">[9]</a>. Furthermore, influenza vaccines have suboptimal immunogenicity and efficacy in the groups at highest risk of severe disease: the very young, the elderly and immunocompromised individuals <a href="#pone.0009106-CDC3" rid="pone.0009106-CDC3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_674951256">[10]</a>.</p><p id="__p9">The current therapeutic regimen for influenza A is limited to two classes of drugs: the adamantanes (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir and zanamivir). Adamantanes rapidly elicit viral resistance, and resistance rates are high among H3N2 viruses and certain clades of H5N1 viruses <a href="#pone.0009106-Deyde1" rid="pone.0009106-Deyde1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177866">[11]</a>&#x02013;<a href="#pone.0009106-CDC4" rid="pone.0009106-CDC4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177864">[14]</a>. The use of oseltamivir, the leading antiviral influenza drug, has been limited by the sudden and widespread emergence of resistance among circulating H1N1 influenza strains <a href="#pone.0009106-Enserink1" rid="pone.0009106-Enserink1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177856">[15]</a>, <a href="#pone.0009106-Moscona1" rid="pone.0009106-Moscona1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177860">[16]</a>. Oseltamivir resistance has also been observed during treatment of H5N1 infection <a href="#pone.0009106-Collins1" rid="pone.0009106-Collins1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177875">[17]</a>, <a href="#pone.0009106-deJong1" rid="pone.0009106-deJong1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177850">[18]</a>. Zanamivir is still effective against H1N1 viruses and resistance to this drug is less likely to arise <a href="#pone.0009106-Moscona2" rid="pone.0009106-Moscona2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177872">[19]</a>. However, its use is limited to patients who can actively use an inhaled drug, which excludes young children, impaired older adults, or patients with underlying airway disease <a href="#pone.0009106-Moscona1" rid="pone.0009106-Moscona1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177859">[16]</a>&#x02013;once again, the group of patients most vulnerable to serious complications from influenza infection.</p><p id="__p10" class="p p-last">In the absence of reliable antiviral drugs and vaccines, development of alternative strategies for influenza prophylaxis and therapy is urgently required. In order to assess whether CR6261 may be a viable option for human treatment, we evaluated the prophylactic and therapeutic efficacy of this human monoclonal antibody in a highly stringent lethal H5N1 influenza ferret model. The ferret is the most suitable disease model for human influenza infection as it displays very human-like disease <a href="#pone.0009106-Barnard1" rid="pone.0009106-Barnard1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_674951254">[20]</a>&#x02013;<a href="#pone.0009106-vanderLaan1" rid="pone.0009106-vanderLaan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177858">[22]</a>.</p></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">Results</h2><div id="s2a" class="sec sec-first"><h3 id="s2atitle">Prophylactic Efficacy of CR6261 against H5N1 Challenge</h3><p id="__p11" class="p p-first">Four groups of 6 ferrets each received 30, 10, 3 or 1 mg/kg CR6261 via an intravenous injection and were challenged the next day with the highly pathogenic avian A/Indonesia/5/2005 (H5N1) virus. A control group of 6 ferrets received 30 mg/kg of the irrelevant isotype-matched antibody CR3014.</p><p id="__p12">All ferrets that received 30 or 10 mg/kg CR6261 survived, compared to only 33.3&#x00025; of the control animals (<a href="/pmc/articles/PMC2817000/figure/pone-0009106-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g001" rid-ob="ob-pone-0009106-g001" co-legend-rid="lgnd_pone-0009106-g001"><span>Figure 1A</span></a>). A further reduction of the dose to 3 mg/kg was clearly correlated with a lower survival rate of 66.7&#x00025;. Though not statistically significant different from survival observed in control animals, there is a 50&#x00025; mortality reduction. The lowest dose of 1 mg/kg CR6261 was not associated with survival benefit compared to control animals. Survival times differed significantly between groups receiving 30 or 10 mg/kg CR6261 and the control group (p&#x0200a;=&#x0200a;0.020).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0009106-g001" co-legend-rid="lgnd_pone-0009106-g001"><a href="/pmc/articles/PMC2817000/figure/pone-0009106-g001/" target="figure" rid-figpopup="pone-0009106-g001" rid-ob="ob-pone-0009106-g001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139833158013744" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2817000_pone.0009106.g001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0009106.g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2817000/bin/pone.0009106.g001.jpg" /></a></div><div id="largeobj_idm139833158013744" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2817000/figure/pone-0009106-g001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0009106-g001"><div><a class="figpopup" href="/pmc/articles/PMC2817000/figure/pone-0009106-g001/" target="figure" rid-figpopup="pone-0009106-g001" rid-ob="ob-pone-0009106-g001">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Prophylactic efficacy of CR6261 against lethal H5N1 challenge.</strong><p id="__p13">Groups of 6 ferrets received 30, 10, 3, or 1 mg/kg of mAb CR6261 or 30 mg/kg control mAb by intravenous injection and were challenged 24 hours later with 10<sup>5</sup> TCID<sub>50</sub> of influenza A/Indonesia/5/2005 (H5N1). Ferrets were monitored for 5 days or until death. Panel A: Kaplan&#x02013;Meier survival probability curves. Panel B: Change in body weight at the end of study (or at death if the event occurred earlier) expressed as percentage from baseline body weight. Panel C: Maximal body temperature observed during the day after challenge. Panel D: Viral shedding of infectious virus in the upper respiratory tract. The graph shows the proportion of ferrets alive with infectious virus detected in nasal and/or throat swabs. Panel E: Viral load in lung tissue as determined by virus titration on MDCK cells. Panel F: lung weights as determined after necropsy. Dots in panels B, C, E and F represent individual animals; group means are indicated by the horizontal lines.</p></div></div></div><p id="__p14">Moribund animals showed general depression, anorexia and lethargy, and exhibited clinical signs of respiratory disease, including dyspnoea. Animals treated at efficacious dose levels (30 and 10 mg/kg) did not loose body weight, whereas the mean weight loss in the control group was 10.5&#x00025; by the time the ferrets died or were euthanized (<a href="/pmc/articles/PMC2817000/figure/pone-0009106-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g001" rid-ob="ob-pone-0009106-g001" co-legend-rid="lgnd_pone-0009106-g001"><span>Figure 1B</span></a>). An exception was one control ferret that succumbed to infection within 48 hours after challenge and lost hardly any weight before. Ferrets that received 3 or 1 mg/kg CR6261 showed similar declines in body weight as the control animals.</p><p id="__p15">One day after challenge the maximum body temperature was observed; for each ferret the maximum body temperature is depicted in <a href="/pmc/articles/PMC2817000/figure/pone-0009106-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g001" rid-ob="ob-pone-0009106-g001" co-legend-rid="lgnd_pone-0009106-g001"><span>figure 1C</span></a>. The groups treated with 30 or 10 mg/kg had mean temperatures of 39.4&#x000b0;C and 40.7&#x000b0;C, respectively, which were significantly lower than the mean of 41.7&#x000b0;C observed in the control group (p&#x0003c;0.001 and p&#x0200a;=&#x0200a;0.015, respectively). The mean temperature observed in animals treated with the lower doses of CR6261 (41.3&#x000b0;C and 41.5&#x000b0;C for 3 and 1 mg/kg, respectively) did not differ significantly from the control group.</p><p id="__p16">The mean temperature in animals observed 3 days before challenge was similar across the 5 groups, ranging from 37.6&#x000b0;C to 38.4&#x000b0;C. Individual body temperature varied considerably within one healthy ferret over 24 hours (standard deviation 0.7&#x000b0;C).</p><p id="__p17">Ferrets treated with 30 or 10 mg/kg CR6261 did not shed infectious virus in the upper respiratory tract at any time, whereas animals in the control group did (<a href="/pmc/articles/PMC2817000/figure/pone-0009106-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g001" rid-ob="ob-pone-0009106-g001" co-legend-rid="lgnd_pone-0009106-g001"><span>Figure 1D</span></a>). Treatment with 3 and 1 mg/kg did not prevent shedding, but reduced the proportion of ferrets with infectious virus in nasal and/or throat swabs.</p><p id="__p18">After necropsy, all ferrets were assessed for viral load in the lungs (<a href="/pmc/articles/PMC2817000/figure/pone-0009106-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g001" rid-ob="ob-pone-0009106-g001" co-legend-rid="lgnd_pone-0009106-g001"><span>figure 1E</span></a>), and the animals that received 30 mg/kg CR6261 or control antibody were also assessed for viral load in the brain, liver, spleen, blood and kidney. The levels of virus replication in the lungs of ferrets treated with 30 and 10 mg/kg CR6261 were 3.9 and 2.9 log<sub>10</sub> TCID<sub>50</sub>/g lower than that in the control group (both p&#x0003c;0.001). No infectious virus was detected in any of the other organs of the ferrets that received 30 mg/kg CR6261, whereas infectious virus was found in the brain of 2, the liver of 3, and the spleen of 5 of the 6 control animals (data not shown). There was no significant difference in lung viral load in the groups receiving 3 or 1 mg/kg CR6261 compared to the control group (p&#x0200a;=&#x0200a;0.74 and p&#x0200a;=&#x0200a;0.91, respectively).</p><p id="__p19">Histopathological results were in accordance with the findings described above; animals that received 30 and 10 mg/kg CR6261 showed much less pulmonary lesions such as primary atypical pneumonia, subacute bronch(iol)itis, emphysema and congestion, or showed such lesions at a lower grade of severity, compared to animals from the other groups. Bronchiolitis obliterans was not observed in any animal that received 30 mg/kg CR6261. Compared to this higher-dose group, animals that received 10 mg/kg CR6261 showed more regenerative response (diffuse grey/red area and bronchioloalveolar hyperplasia) in the lungs, and more inflammatory changes in the trachea. Pulmonary oedema was not observed in animals that received 30 or 10 mg/kg CR6261, but was observed frequently in all other groups. These findings were in agreement with mean lung weights, which were lowest in the animals treated with 30 or 10 mg/kg CR6261 (6.3 g and 7.6 g, respectively) and significantly lower in this group than in control animals (15.0 g; both comparisons p&#x0003c;0.001). No significant difference in lung weight was found between the groups receiving 3 or 1 mg/kg CR6261 (14.1 g and 15.4 g, respectively) and the control group (15.0 g).</p><p id="__p20" class="p p-last">These findings show that, in a dose dependent way, prophylactically administered CR6261 confers protection against lethal H5N1 challenge, prevents morbidity and viral dissemination and reduces pulmonary pathology.</p></div><div id="s2b" class="sec sec-last"><h3 id="s2btitle">Therapeutic Efficacy of CR6261 against H5N1 Challenge</h3><p id="__p21" class="p p-first">To assess the therapeutic efficacy of the monoclonal antibody CR6261, two groups of 10 ferrets were challenged as above and given 30 mg/kg of CR6261 either 4 or 24 hours later. A comparator group of 10 ferrets received 30 mg/kg of the control antibody 4 hours after challenge.</p><p id="__p22">Survival rates in the groups receiving CR6261 at 4 and 24 hours after challenge were 100&#x00025;, whereas only 20&#x00025; of the animals in the control group survived (p&#x0003c;0.001) (<a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><span>Figure 2A</span></a>). Mean decline in body weight at the end of the experiment was 6.2&#x00025; in the group of ferrets that received CR6261 4 hours after challenge (<a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><span>Figure 2B</span></a>), which was significantly less (p&#x0200a;=&#x0200a;0.025) than the 10.1&#x00025; observed in control animals. Animals treated 24 hours post challenge showed a mean body weight loss of 8.4&#x00025;, which was not significantly different from the control animals (p&#x0200a;=&#x0200a;0.427). The group of ferrets treated with CR6261 4 hours post challenge had a mean maximum temperature of 40.0&#x000b0;C, compared to 41.8&#x000b0;C in the control group (p&#x0003c;0.001). In line with the rapid rise in temperature after challenge observed in the prophylaxis experiment ferrets treated with CR6261 24 hours after challenge showed a mean maximal temperature of 41.5&#x000b0;C before CR6261 was administered (p&#x0200a;=&#x0200a;0.15 versus 41.8&#x000b0;C of the control group, <a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><span>figure 2C</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139833164781008" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2817000_pone.0009106.g002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0009106.g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2817000/bin/pone.0009106.g002.jpg" /></a></div><div id="largeobj_idm139833164781008" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0009106-g002"><div><a class="figpopup" href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Therapeutic efficacy of CR6261 against lethal H5N1 challenge.</strong><p id="__p23">Groups of 10 ferrets received 30 mg/kg mAb CR6261 by intravenous injection either 4 or 24 hours after challenge with 10<sup>5</sup> TCID<sub>50</sub> of influenza A/Indonesia/5/2005 (H5N1) virus. A control group of 10 ferrets received 30 mg/kg of a control mAb 4 hours after challenge. Ferrets were monitored for 5 days or until death. Panel A: Kaplan&#x02013;Meier survival probability curves. Panel B: Change in body weight at the end of study (or at death if earlier) expressed as percentage from baseline weight. Panel C: Maximal body temperature observed the day after challenge. Panel D: Viral shedding of infectious virus in the upper respiratory tract. The graph shows the proportion of ferrets alive with infectious virus detected in nasal and/or throat swabs. Panel E: Viral load in lung tissue as determined by virus titration on MDCK cells. Panel F: lung weights as determined after necropsy. Dots in panels B, C, E and F represent individual animals; group means are indicated by horizontal lines. The open circles (panel E and F) indicate one additional ferret per CR6261 group that was euthanized at day 3 for virus isolation and pathology.</p></div></div></div><p id="__p24">Ferrets treated with CR6261 at 4 hours post challenge did not shed infectious virus in the upper respiratory tract throughout the study (<a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><span>figure 2D</span></a>). In the group treated with CR6261 at 24 hours post challenge, one ferret had a low concentration of infectious virus (2.8 log<sub>10</sub> TCID<sub>50</sub>) in the throat on day one, but no virus was detected on subsequent days. In contrast, all animals in the control group shed virus during one or more days. Accordingly, the mean viral loads in the lungs of ferrets treated with CR6261 at 4 and 24 hours post challenge were considerably lower than that in the control group (differences were 3.9 and 4.5 log<sub>10</sub> TCID<sub>50</sub>/g, respectively, both comparisons p&#x0003c;0.001; <a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><span>Figure 2E</span></a>).</p><p id="__p25">The lungs of animals that received CR6261 at 4 hours post challenge showed less pulmonary lesions (alveolar oedema, bronchiolitis obliterans, congestion, emphysema, bronchioloalveolar hyperplasia and primary atypical pneumonia), or showed such lesions at a lower grade of severity, compared to the lungs of animals from the other two groups. Animals of the control group were most affected by primary atypical pneumonia. These findings were in accordance with the observation that the mean lung weights of ferrets treated with CR6261 at 4 hours post challenge were lower compared to the control group (5.7 g versus 14.9 g, p&#x0003c;0.001; <a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><span>Figure 2F</span></a>). Animals that received CR6261 at 24 hours post challenge showed most regenerative response (bronchioloalveolar hyperplasia) in the lungs, suggesting damage to the lung parenchyma with subsequent regenerative response. The mean lung weight in this group was significantly higher than that of the group receiving CR6261 at 4 hours post challenge (8.4 g versus 5.7 g), but lower than that of the control group (p&#x0003c;0.001).</p><p id="__p26" class="p p-last">From the study outset, one animal had been added to each of the two treatment groups to be sacrificed for gross-pathology and histology on lungs as soon as 50&#x00025; of the control animals died. The purpose was to test for possible bias due to differences in the timing of death. Infectious virus titres in the lungs of the treated ferrets sacrificed at day 3 were identical to those in treated animals sacrificed at the end of the study (open circles in <a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><span>figure 2E</span></a>). Similarly, there were no differences in lung weight and pathology between animals sacrificed at day 3 or after day 5 (<a href="/pmc/articles/PMC2817000/figure/pone-0009106-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0009106-g002" rid-ob="ob-pone-0009106-g002" co-legend-rid="lgnd_pone-0009106-g002"><span>figure 2F</span></a>). This indicates that the results were not biased by differences in the timing of euthanasia or spontaneous death.</p></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">Discussion</h2><p id="__p27" class="p p-first">CR6261 represents a new class of human monoclonal antibodies that exhibits immediate and potent efficacy for the prevention or treatment of influenza in a clinically relevant model for severe disease. The results presented here also confirm previously reported data demonstrating the prophylactic and therapeutic efficacy of CR6261 in mice challenged with H5N1 influenza viruses. Together with the H1N1 challenged mice data published earlier <a href="#pone.0009106-Throsby1" rid="pone.0009106-Throsby1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177873">[1]</a> these findings indicate that CR6261 is effective across a broad spectrum of influenza viruses, including seasonal and potentially pandemic strains.</p><p id="__p28">Passive immunotherapy would be particularly beneficial for the groups at highest risk of severe disease due to seasonal influenza&#x02013;the elderly and immuno-compromised&#x02013;but may also be indispensable for the general public in the event of a pandemic disease outbreak caused by high-risk pandemic candidates such as H2, H5, H6 and H9.</p><p id="__p29">Monoclonal antibodies against influenza viruses have been studied for decades, but their potential&#x02013;and thus development&#x02013;as &#x02018;passive&#x02019; immunotherapy for influenza has been inhibited by the lack of monoclonal antibodies with broad neutralizing activity. This lack is due to the tolerance of influenza virus for genetic changes in the most immunogenic regions on its surface. The recent discovery of broadly neutralizing human monoclonal influenza antibodies <a href="#pone.0009106-Throsby1" rid="pone.0009106-Throsby1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177865">[1]</a> and the demonstrated efficacy of a representative of this novel class of antibodies against lethal viral challenge in a clinically relevant model, as presented in this paper, create an opportunity for the prevention and treatment of influenza infections, regardless of the causal strain. The possibility of a potent and broadly neutralizing agent that would equip clinicians and public health workers to deal effectively with the influenza viruses of the future represents a paradigm shift in the approach to influenza control.</p><p id="__p30">Influenza illness observed in the ferrets infected with H5N1 virus in this study closely resembles influenza in humans with H5N1 infection, who present with fever, cough, shortness of breath, and radiological evidence of pneumonia <a href="#pone.0009106-Kandun1" rid="pone.0009106-Kandun1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177854">[23]</a>. Besides respiratory symptoms, gastrointestinal symptoms such as diarrhoea, vomiting and abdominal pain are often present. In severe cases, the pneumonia rapidly progresses to acute respiratory distress syndrome and multiorgan failure. High viral loads, extrapulmonary virus dissemination and hypercytokinaemia are associated with fatal outcome (reviewed in <a href="#pone.0009106-AbdelGhafar1" rid="pone.0009106-AbdelGhafar1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177877">[24]</a>&#x02013;<a href="#pone.0009106-Thanh1" rid="pone.0009106-Thanh1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177848">[26]</a>). Autopsies of patients who succumbed to influenza A (H5N1) virus infection have shown diffuse alveolar damage, patchy interstitial lymphoplasmacytic infiltrates, bronchiolitis with squamous metaplasia and pulmonary congestion with various degrees of haemorrhage <a href="#pone.0009106-Gu1" rid="pone.0009106-Gu1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177879">[27]</a>&#x02013;<a href="#pone.0009106-Uiprasertkul1" rid="pone.0009106-Uiprasertkul1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177849">[29]</a>. The clinical signs observed in the control animals of this ferret study correspond to the most severe influenza pathology in humans <a href="#pone.0009106-Kandun1" rid="pone.0009106-Kandun1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177855">[23]</a>. The efficacy of CR6261 in preventing these clinical signs in the prophylactic and therapeutic ferret model presented here, together with the efficacy shown in mice after lethal challenges with different viruses, strongly indicate that CR6261 can be expected to be efficacious against disease caused by the other, less virulent viruses it neutralized in vitro <a href="#pone.0009106-Throsby1" rid="pone.0009106-Throsby1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177878">[1]</a>.</p><p id="__p31">In a meta-analysis of experimental influenza infection of placebo-treated and untreated healthy volunteers, Carrat <em>et al.</em>\n<a href="#pone.0009106-Carrat1" rid="pone.0009106-Carrat1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177861">[30]</a> studied 1280 participants who were challenged with either influenza type H1N1, H3N2 or B. Interestingly, viral shedding was highly correlated with the presence of clinical symptoms such as fever, runny nose, sore throat, sneezing, cough and shortness of breath. The authors concluded from their meta-analysis that subjects with symptomatic illness shed virus in amounts 100 to 1000 fold higher than subjects who were not ill. The fact that CR6261 after intravenous administration instantaneously reduces viral shedding indicates that in man CR6261 might reduce clinical symptoms in subjects infected with influenza virus. In addition, studies in guinea pigs showed that a reduction in nasal wash titers correlate with a decreased efficiency of viral transmission by aerosol <a href="#pone.0009106-Lowen1" rid="pone.0009106-Lowen1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177851">[31]</a>. The ability of CR6261 to abolish shedding of virus in pharyngeal secretions strongly suggests that antibodies like CR6261 might prevent or reduce virus spreading at the onset of an epidemic influenza outbreak in nursing homes or in case of a pandemic.</p><p id="__p32">In this study, we assessed the efficacy of the human monoclonal antibody CR6261 against a highly pathogenic avian H5N1 virus, as this provides a stringent disease model for severe influenza. However, the potential use of this antibody is not limited to viruses of this subtype or to other avian strains that may pose a pandemic threat. CR6261 has been shown to recognize H1 viruses that have emerged over a time span of 90 years from the H1N1 virus which caused the 1918 &#x02018;Spanish flu&#x02019; pandemic to the latest Brisbane viruses. Since the epitope is conserved CR6261 is predicted to bind to future antigenic drift variants. This means that CR6261 could be used to protect against all H1 influenza viruses, including the ones resistant to oseltamivir. Use of CR6261 in combination with effective medication against H3, such as oseltamivir or zanamivir, would effectively protect against all seasonal influenza viruses, without a need for prior knowledge of the virus subtype or strain.</p><p id="__p33" class="p p-last">In the present study ferrets were challenged with an inoculum which is probably much higher compared to the viral exposure in naturally infection in humans. The rapid deterioration in ferrets with death occurring within 3 days underpins this hypothesis since humans exposed to H5N1 develop the first symptoms 2&#x02013;4 days after the last exposure and even periods of up to 8 days have been reported <a href="#pone.0009106-Gambotto1" rid="pone.0009106-Gambotto1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177867">[25]</a>. The clinical signs in this model are quite extreme, but important for establishing the efficacy of the antibody as proof of concept. The data of these two experiments demonstrate the prophylactic and therapeutic efficacy of this new class of human monoclonal antibodies in a highly stringent and clinically relevant ferret model of human influenza.</p></div><div id="s4" class="tsec sec"><h2 class="head no_bottom_margin" id="s4title">Materials and Methods</h2><div id="s4a" class="sec sec-first"><h3 id="s4atitle">Antibody</h3><p id="__p34" class="p p-first-last">The human monoclonal antibody CR6261 was isolated from the IgM&#x0002b;, CD27&#x0002b; B cell repertoire of a healthy individual who was recently vaccinated with the seasonal influenza vaccine, using phage display selection on recombinant H5 haemagglutinin <a href="#pone.0009106-Throsby1" rid="pone.0009106-Throsby1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177871">[1]</a>. CR3014, an isotype-matched antibody with the ability to neutralize SARS corona virus&#x02013;which has similar tissue/organ tropism as that of H5 viruses&#x02013;was used as a control antibody <a href="#pone.0009106-terMeulen1" rid="pone.0009106-terMeulen1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_848031650">[32]</a>. Both antibodies were produced on PER.C6&#x000ae; cells.</p></div><div id="s4b" class="sec"><h3 id="s4btitle">Animal Studies</h3><p id="__p35" class="p p-first">The study was performed with outbred ferrets (<em>Mustela putorius furo</em>, female, age approximately 8 months, Schimmel Farms, Uddel, the Netherlands). Ferrets were screened for the presence of serum antibodies against Aleutian Disease virus, circulating seasonal influenza virus strains (A/H1N1, A/H3N2 and B) and the challenge virus (H5N1, A/Indonesia/5/2005), and only seronegative animals were used in the study. The animals were housed in study groups of 6 (prophylactic experiment) or 10 (therapeutic experiment).</p><p id="__p36">Antibodies were administered by intravenous injection in the jugular vein. Viral challenge was performed intratracheally with 10<sup>5</sup> TCID<sub>50</sub> A/Indonesia/05/2005 in 3 mL of PBS <a href="#pone.0009106-Baras1" rid="pone.0009106-Baras1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177876">[33]</a>. Clinical observations were performed twice a day on days of intervention and once daily on other days. In the prophylactic experiment, animals were weighed 2 weeks before viral challenge (day &#x02212;14), immediately prior to antibody administration (day &#x02212;1), and after challenge (days 2, 4, and 5 or on the day of premature death). In the therapeutic experiment, animals were weighed on day &#x02212;14 and day &#x02212;2, immediately prior to challenge and antibody administration, and on days 2, 4 and the last study day. Body temperature was recorded every 15 minutes throughout both experiments using a device (DST micro-T, Star-Oddi, Reykjavik, Iceland) implanted in the peritoneal cavity 14 days before challenge.</p><p id="__p37" class="p p-last">The animal experiments were carried out in the central animal facilities of the Netherlands Vaccine Institute (NVI, Bilthoven) under conditions that meet the Dutch legal requirements for animal experimentation and are in accordance with the &#x02018;Guide for the care and use of laboratory animals&#x02019;, the recommendations of the Institute for Laboratory Animal Research (US National Institutes of Health), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) standards.</p></div><div id="s4c" class="sec"><h3 id="s4ctitle">Viral Shedding</h3><p id="__p38" class="p p-first-last">Viral titrations were performed as described elsewhere <a href="#pone.0009106-Rimmelzwaan1" rid="pone.0009106-Rimmelzwaan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_672177863">[34]</a>. Briefly, pharyngeal and nasal swabs were collected from all animals at day &#x02212;1, day 2, day 4, and day 5. Individual swabs were homogenized and resuspended in 3 ml medium and stored at &#x02212;80&#x000b0;C until analysis. Viral titres were determined by virus titration on Madine Darby canine kidney (MDCK) cells. Viral shedding from the upper respiratory tract was analysed by calculating the proportion of ferrets with detectable levels of infectious virus in nasal and/or throat swabs relative to the number of living ferrets.</p></div><div id="s4d" class="sec"><h3 id="s4dtitle">Viral Load</h3><p id="__p39" class="p p-first-last">After necropsy, the cranioventral, craniodorsal, caudoventral and caudodorsal sections of the right lung were collected from each animal, weighed, homogenized and resuspended in 3 ml medium, and stored at &#x02212;80&#x000b0;C until analysis. Viral titres were determined after thawing of the tissue sections followed by homogenization and resuspension by virus titration on MDCK cells. In addition, viral titres in tissues of brain, spleen, liver, kidney, and plasma from animals that received either 30 mg/kg of CR6261 or CR3014 one day prior to challenge were determined using the same method.</p></div><div id="s4e" class="sec"><h3 id="s4etitle">Pathology</h3><p id="__p40" class="p p-first-last">A complete macroscopic post-mortem examination was performed on all animals. This included examination of the external surfaces and all orifices; the thoracic, abdominal and pelvic cavities with their associated organs and tissues; and the neck with its associated organs and tissues. Lungs were weighed and all lung lobes were inspected and lesions described. The left lung (including trachea) was collected during autopsy, inflated with 10&#x00025; neutral buffered formalin for fixation/histology and microscopic examination. Paraffin embedded tissue sections (left cranial lobe, left caudal lobe, right cranial-, middle- and caudal lobes and accessory lobe) were stained with haematoxylin and eosin and assessed by light microscopy for aspects like congestion, emphysema, presence of foreign body, haemorrhagy, bronchioloalveolar hyperplasia and inflammation, and oedema.</p></div><div id="s4f" class="sec"><h3 id="s4ftitle">Anaesthesia</h3><p id="__p41" class="p p-first-last">Prior to blood sampling, the taking of nose and throat swabs and euthanasia, the ferrets were anaesthetised with ketamin (25 mg/kg; i.m.). For implantation of temperature sensors, antibody administration and viral challenge, the animals were anaesthetized with a mixture of ketamin (12.5 mg/kg; i.m.) and domitor (7.5 &#x000b5;g/kg; i.m.), followed by antisedan (0.5 mg/kg; i.m.).</p></div><div id="s4g" class="sec sec-last"><h3 id="s4gtitle">Statistical Analyses</h3><p id="__p42" class="p p-first">Survival times after viral challenge were analysed using the log-rank test and survival proportions using the Fisher\'s exact test. Body weight expressed as percentage change from baseline was calculated at the end of the study period (or earlier in the event of earlier death). Maximum body temperatures were observed during day one and these values were subsequently used for calculating the mean maximum body temperature for each group. Variables were analysed in an one-way analysis of variance (ANOVA) with post-hoc testing to compare to the control group using Dunnett\'s adjustment for multiple comparisons.</p><p id="__p43" class="p p-last">Lung weight and lung viral titres were compared across arms using ANOVA, with day of necropsy entered as a covariate. Differences between treatment groups were estimated using marginal means, with Sidak\'s adjustment for multiple comparisons. Statistical analyses were performed using SPSS version 15.0 (SPSS Inc. USA). Statistical significance level was set at &#x003b1;&#x0200a;=&#x0200a;0.05.</p></div></div><div id="idm139833156552624" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139833156552624title">Acknowledgments</h2><div class="sec"><p id="__p44">We thank Andrea Dingemans for her critical review of the manuscript, Willem van Aert and Geert van Amerongen for excellent technical assistance, James Simon for supervising the ViroClinics input, Vera Teeuwsen for preparing the protocols, and Elina van Herwijnen for independent data check, and Jaco Klap for statistical support.</p></div></div><div id="idm139833156551648" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139833156551648title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm139833156551520"><p id="__p45" class="p p-first-last"><strong>Competing Interests: </strong>The authors state that they have a financial interest. R.F., W.K., M.K., G.J.W., J.B., P.L., R.K., and J.G. are employees of Crucell Holland BV. K.S. and A.O. are employees of ViroClinics BV. A.O. is furthermore an employee of the Erasmus MC, Rotterdam.</p></p><p class="fn sec" id="idm139833156550128"><p id="__p46" class="p p-first-last"><strong>Funding: </strong>This work was funded by Crucell Holland BV (<a href="http://www.crucell.com" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.crucell.com</a>). The funder had a role in study design, data analysis, decision to publish and preparation of the manuscript, but not in execution of the experiments and collection of the data.</p></p></div></div><div id="idm139833201949616" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139833201949616title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="pone.0009106-Throsby1">1. <span class="element-citation">Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM&#x0002b; memory B cells. <span><span class="ref-journal">PLoS ONE. </span>2008;<span class="ref-vol">3</span>:e3942.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2596486/">PMC free article</a>]</span> [<a href="/pubmed/19079604" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=Heterosubtypic+neutralizing+monoclonal+antibodies+cross-protective+against+H5N1+and+H1N1+recovered+from+human+IgM&#x0002b;+memory+B+cells.&amp;author=M+Throsby&amp;author=E+van+den+Brink&amp;author=M+Jongeneelen&amp;author=LL+Poon&amp;author=P+Alard&amp;volume=3&amp;publication_year=2008&amp;pages=e3942&amp;pmid=19079604&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Ekiert1">2. <span class="element-citation">Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope. <span><span class="ref-journal">Science </span>2009</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2758658/">PMC free article</a>]</span> [<a href="/pubmed/19251591" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Antibody+Recognition+of+a+Highly+Conserved+Influenza+Virus+Epitope.&amp;author=DC+Ekiert&amp;author=G+Bhabha&amp;author=MA+Elsliger&amp;author=RH+Friesen&amp;author=M+Jongeneelen&amp;publication_year=2009&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Sui1">3. <span class="element-citation">Sui J, Hwang WC, Perez S, Wei G, Aird D, et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. <span><span class="ref-journal">Nat Struct Mol Biol. </span>2009;<span class="ref-vol">16</span>:265\xe2\x80\x93273.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2692245/">PMC free article</a>]</span> [<a href="/pubmed/19234466" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Struct+Mol+Biol&amp;title=Structural+and+functional+bases+for+broad-spectrum+neutralization+of+avian+and+human+influenza+A+viruses.&amp;author=J+Sui&amp;author=WC+Hwang&amp;author=S+Perez&amp;author=G+Wei&amp;author=D+Aird&amp;volume=16&amp;publication_year=2009&amp;pages=265-273&amp;pmid=19234466&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-WHO1">4. <span class="element-citation">WHO. Fact sheet 211: Influenza. <span class="ref-journal">World Health Organization.</span> 2009. </span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Hoelscher1">5. <span class="element-citation">Hoelscher M, Gangappa S, Zhong W, Jayashankar L, Sambhara S. Vaccines against epidemic and pandemic influenza. <span><span class="ref-journal">Expert Opin Drug Deliv. </span>2008;<span class="ref-vol">5</span>:1139\xe2\x80\x931157.</span> [<a href="/pubmed/18817518" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Drug+Deliv&amp;title=Vaccines+against+epidemic+and+pandemic+influenza.&amp;author=M+Hoelscher&amp;author=S+Gangappa&amp;author=W+Zhong&amp;author=L+Jayashankar&amp;author=S+Sambhara&amp;volume=5&amp;publication_year=2008&amp;pages=1139-1157&amp;pmid=18817518&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-CDC1">6. <span class="element-citation">CDC Swine influenza A (H1N1) infection in two children&#x02013;Southern California, March&#x02013;April 2009. <span><span class="ref-journal">MMWR Morb Mortal Wkly Rep. </span>2009;<span class="ref-vol">58</span>:400\xe2\x80\x93402.</span> [<a href="/pubmed/19390508" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=MMWR+Morb+Mortal+Wkly+Rep&amp;title=Swine+influenza+A+(H1N1)+infection+in+two+children&#x02013;Southern+California,+March&#x02013;April+2009.&amp;author=+CDC&amp;volume=58&amp;publication_year=2009&amp;pages=400-402&amp;pmid=19390508&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-WHO2">7. <span class="element-citation">WHO. World now at the start of 2009 influenza pandemic. 2009. </span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Salzberg1">8. <span class="element-citation">Salzberg S. The contents of the syringe. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">454</span>:160\xe2\x80\x93161.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2674578/">PMC free article</a>]</span> [<a href="/pubmed/18615063" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=The+contents+of+the+syringe.&amp;author=S+Salzberg&amp;volume=454&amp;publication_year=2008&amp;pages=160-161&amp;pmid=18615063&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-CDC2">9. <span class="element-citation">CDC Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine&#x02013;Marshfield, Wisconsin, 2007&#x02013;08 influenza season. <span><span class="ref-journal">MMWR Morb Mortal Wkly Rep. </span>2008;<span class="ref-vol">57</span>:393\xe2\x80\x93398.</span> [<a href="/pubmed/18418344" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=MMWR+Morb+Mortal+Wkly+Rep&amp;title=Interim+within-season+estimate+of+the+effectiveness+of+trivalent+inactivated+influenza+vaccine&#x02013;Marshfield,+Wisconsin,+2007&#x02013;08+influenza+season.&amp;author=+CDC&amp;volume=57&amp;publication_year=2008&amp;pages=393-398&amp;pmid=18418344&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-CDC3">10. <span class="element-citation">CDC. Prevention and Control of Influenza; Recommendations of the Advisory Commitee on Immunization Practices (ACIP). <span><span class="ref-journal">MMWR Morb Mortal Wkly Rep. </span>2006;<span class="ref-vol">55</span>:1\xe2\x80\x9342.</span> [<a href="/pubmed/16874296" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=MMWR+Morb+Mortal+Wkly+Rep&amp;title=Prevention+and+Control+of+Influenza;+Recommendations+of+the+Advisory+Commitee+on+Immunization+Practices+(ACIP).&amp;volume=55&amp;publication_year=2006&amp;pages=1-42&amp;pmid=16410759&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Deyde1">11. <span class="element-citation">Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, et al.  Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. <span><span class="ref-journal">J Infect Dis. </span>2007;<span class="ref-vol">196</span>:249\xe2\x80\x93257.</span> [<a href="/pubmed/17570112" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Surveillance+of+resistance+to+adamantanes+among+influenza+A(H3N2)+and+A(H1N1)+viruses+isolated+worldwide.&amp;author=VM+Deyde&amp;author=X+Xu&amp;author=RA+Bright&amp;author=M+Shaw&amp;author=CB+Smith&amp;volume=196&amp;publication_year=2007&amp;pages=249-257&amp;pmid=17570112&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-He1">12. <span class="element-citation">He G, Qiao J, Dong C, He C, Zhao L, et al.  Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. <span><span class="ref-journal">Antiviral Res. </span>2008;<span class="ref-vol">77</span>:72\xe2\x80\x9376.</span> [<a href="/pubmed/17897729" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antiviral+Res&amp;title=Amantadine-resistance+among+H5N1+avian+influenza+viruses+isolated+in+Northern+China.&amp;author=G+He&amp;author=J+Qiao&amp;author=C+Dong&amp;author=C+He&amp;author=L+Zhao&amp;volume=77&amp;publication_year=2008&amp;pages=72-76&amp;pmid=17897729&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Bright1">13. <span class="element-citation">Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005&#x02013;2006 influenza season in the United States. <span><span class="ref-journal">JAMA. </span>2006;<span class="ref-vol">295</span>:891\xe2\x80\x93894.</span> [<a href="/pubmed/16456087" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Adamantane+resistance+among+influenza+A+viruses+isolated+early+during+the+2005&#x02013;2006+influenza+season+in+the+United+States.&amp;author=RA+Bright&amp;author=DK+Shay&amp;author=B+Shu&amp;author=NJ+Cox&amp;author=AI+Klimov&amp;volume=295&amp;publication_year=2006&amp;pages=891-894&amp;pmid=16456087&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-CDC4">14. <span class="element-citation">CDC. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents&#x02013;United States, 2005&#x02013;06 influenza season. <span><span class="ref-journal">MMWR Morb Mortal Wkly Rep. </span>2006;<span class="ref-vol">55</span>:44\xe2\x80\x9346.</span> [<a href="/pubmed/16424859" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=MMWR+Morb+Mortal+Wkly+Rep&amp;title=High+levels+of+adamantane+resistance+among+influenza+A+(H3N2)+viruses+and+interim+guidelines+for+use+of+antiviral+agents&#x02013;United+States,+2005&#x02013;06+influenza+season.&amp;volume=55&amp;publication_year=2006&amp;pages=44-46&amp;pmid=16424859&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Enserink1">15. <span class="element-citation">Enserink M. Drug resistance. A &#x02018;wimpy&#x02019; flu strain mysteriously turns scary. <span><span class="ref-journal">Science. </span>2009;<span class="ref-vol">323</span>:1162\xe2\x80\x931163.</span> [<a href="/pubmed/19251605" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Drug+resistance.+A+&#x02018;wimpy&#x02019;+flu+strain+mysteriously+turns+scary.&amp;author=M+Enserink&amp;volume=323&amp;publication_year=2009&amp;pages=1162-1163&amp;pmid=19251605&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Moscona1">16. <span class="element-citation">Moscona A. Global transmission of oseltamivir-resistant influenza. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">360</span>:953\xe2\x80\x93956.</span> [<a href="/pubmed/19258250" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Global+transmission+of+oseltamivir-resistant+influenza.&amp;author=A+Moscona&amp;volume=360&amp;publication_year=2009&amp;pages=953-956&amp;pmid=19258250&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Collins1">17. <span class="element-citation">Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">453</span>:1258\xe2\x80\x931261.</span> [<a href="/pubmed/18480754" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Crystal+structures+of+oseltamivir-resistant+influenza+virus+neuraminidase+mutants.&amp;author=PJ+Collins&amp;author=LF+Haire&amp;author=YP+Lin&amp;author=J+Liu&amp;author=RJ+Russell&amp;volume=453&amp;publication_year=2008&amp;pages=1258-1261&amp;pmid=18480754&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-deJong1">18. <span class="element-citation">de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">353</span>:2667\xe2\x80\x932672.</span> [<a href="/pubmed/16371632" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Oseltamivir+resistance+during+treatment+of+influenza+A+(H5N1)+infection.&amp;author=MD+de+Jong&amp;author=TT+Tran&amp;author=HK+Truong&amp;author=MH+Vo&amp;author=GJ+Smith&amp;volume=353&amp;publication_year=2005&amp;pages=2667-2672&amp;pmid=16371632&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Moscona2">19. <span class="element-citation">Moscona A. Medical management of influenza infection. <span><span class="ref-journal">Annu Rev Med. </span>2008;<span class="ref-vol">59</span>:397\xe2\x80\x93413.</span> [<a href="/pubmed/17939760" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Med&amp;title=Medical+management+of+influenza+infection.&amp;author=A+Moscona&amp;volume=59&amp;publication_year=2008&amp;pages=397-413&amp;pmid=17939760&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Barnard1">20. <span class="element-citation">Barnard DL. Animal models for the study of influenza pathogenesis and therapy. <span><span class="ref-journal">Antiviral Res </span>2009</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2700745/">PMC free article</a>]</span> [<a href="/pubmed/19176218" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antiviral+Res&amp;title=Animal+models+for+the+study+of+influenza+pathogenesis+and+therapy.&amp;author=DL+Barnard&amp;publication_year=2009&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Hampson1">21. <span class="element-citation">Hampson AW. Ferrets and the challenges of H5N1 vaccine formulation. <span><span class="ref-journal">J Infect Dis. </span>2006;<span class="ref-vol">194</span>:143\xe2\x80\x93145.</span> [<a href="/pubmed/16779718" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Ferrets+and+the+challenges+of+H5N1+vaccine+formulation.&amp;author=AW+Hampson&amp;volume=194&amp;publication_year=2006&amp;pages=143-145&amp;pmid=16779718&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-vanderLaan1">22. <span class="element-citation">van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, et al.  Animal models in influenza vaccine testing. <span><span class="ref-journal">Expert Rev Vaccines. </span>2008;<span class="ref-vol">7</span>:783\xe2\x80\x93793.</span> [<a href="/pubmed/18665776" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Vaccines&amp;title=Animal+models+in+influenza+vaccine+testing.&amp;author=JW+van+der+Laan&amp;author=C+Herberts&amp;author=R+Lambkin-Williams&amp;author=A+Boyers&amp;author=AJ+Mann&amp;volume=7&amp;publication_year=2008&amp;pages=783-793&amp;pmid=18665776&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Kandun1">23. <span class="element-citation">Kandun IN, Tresnaningsih E, Purba WH, Lee V, Samaan G, et al.  Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. <span><span class="ref-journal">Lancet. </span>2008;<span class="ref-vol">372</span>:744\xe2\x80\x93749.</span> [<a href="/pubmed/18706688" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Factors+associated+with+case+fatality+of+human+H5N1+virus+infections+in+Indonesia:+a+case+series.&amp;author=IN+Kandun&amp;author=E+Tresnaningsih&amp;author=WH+Purba&amp;author=V+Lee&amp;author=G+Samaan&amp;volume=372&amp;publication_year=2008&amp;pages=744-749&amp;pmid=18706688&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-AbdelGhafar1">24. <span class="element-citation">Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al.  Update on avian influenza A (H5N1) virus infection in humans. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">358</span>:261\xe2\x80\x93273.</span> [<a href="/pubmed/18199865" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Update+on+avian+influenza+A+(H5N1)+virus+infection+in+humans.&amp;author=AN+Abdel-Ghafar&amp;author=T+Chotpitayasunondh&amp;author=Z+Gao&amp;author=FG+Hayden&amp;author=DH+Nguyen&amp;volume=358&amp;publication_year=2008&amp;pages=261-273&amp;pmid=18199865&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Gambotto1">25. <span class="element-citation">Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. <span><span class="ref-journal">Lancet. </span>2008;<span class="ref-vol">371</span>:1464\xe2\x80\x931475.</span> [<a href="/pubmed/18440429" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Human+infection+with+highly+pathogenic+H5N1+influenza+virus.&amp;author=A+Gambotto&amp;author=SM+Barratt-Boyes&amp;author=MD+de+Jong&amp;author=G+Neumann&amp;author=Y+Kawaoka&amp;volume=371&amp;publication_year=2008&amp;pages=1464-1475&amp;pmid=18440429&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Thanh1">26. <span class="element-citation">Thanh TT, van Doorn HR, de Jong MD. Human H5N1 influenza: current insight into pathogenesis. <span><span class="ref-journal">Int J Biochem Cell Biol. </span>2008;<span class="ref-vol">40</span>:2671\xe2\x80\x932674.</span> [<a href="/pubmed/18588994" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Biochem+Cell+Biol&amp;title=Human+H5N1+influenza:+current+insight+into+pathogenesis.&amp;author=TT+Thanh&amp;author=HR+van+Doorn&amp;author=MD+de+Jong&amp;volume=40&amp;publication_year=2008&amp;pages=2671-2674&amp;pmid=18588994&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Gu1">27. <span class="element-citation">Gu J, Xie Z, Gao Z, Liu J, Korteweg C, et al.  H5N1 infection of the respiratory tract and beyond: a molecular pathology study. <span><span class="ref-journal">Lancet. </span>2007;<span class="ref-vol">370</span>:1137\xe2\x80\x931145.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7159293/">PMC free article</a>]</span> [<a href="/pubmed/17905166" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=H5N1+infection+of+the+respiratory+tract+and+beyond:+a+molecular+pathology+study.&amp;author=J+Gu&amp;author=Z+Xie&amp;author=Z+Gao&amp;author=J+Liu&amp;author=C+Korteweg&amp;volume=370&amp;publication_year=2007&amp;pages=1137-1145&amp;pmid=17905166&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Ng1">28. <span class="element-citation">Ng WF, To KF, Lam WW, Ng TK, Lee KC. The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1&#x02013;a review. <span><span class="ref-journal">Hum Pathol. </span>2006;<span class="ref-vol">37</span>:381\xe2\x80\x93390.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7112039/">PMC free article</a>]</span> [<a href="/pubmed/16564911" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Pathol&amp;title=The+comparative+pathology+of+severe+acute+respiratory+syndrome+and+avian+influenza+A+subtype+H5N1&#x02013;a+review.&amp;author=WF+Ng&amp;author=KF+To&amp;author=WW+Lam&amp;author=TK+Ng&amp;author=KC+Lee&amp;volume=37&amp;publication_year=2006&amp;pages=381-390&amp;pmid=16564911&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Uiprasertkul1">29. <span class="element-citation">Uiprasertkul M, Kitphati R, Puthavathana P, Kriwong R, Kongchanagul A, et al.  Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. <span><span class="ref-journal">Emerg Infect Dis. </span>2007;<span class="ref-vol">13</span>:708\xe2\x80\x93712.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2738443/">PMC free article</a>]</span> [<a href="/pubmed/17553248" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;title=Apoptosis+and+pathogenesis+of+avian+influenza+A+(H5N1)+virus+in+humans.&amp;author=M+Uiprasertkul&amp;author=R+Kitphati&amp;author=P+Puthavathana&amp;author=R+Kriwong&amp;author=A+Kongchanagul&amp;volume=13&amp;publication_year=2007&amp;pages=708-712&amp;pmid=17553248&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Carrat1">30. <span class="element-citation">Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. <span><span class="ref-journal">Am J Epidemiol. </span>2008;<span class="ref-vol">167</span>:775\xe2\x80\x93785.</span> [<a href="/pubmed/18230677" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Epidemiol&amp;title=Time+lines+of+infection+and+disease+in+human+influenza:+a+review+of+volunteer+challenge+studies.&amp;author=F+Carrat&amp;author=E+Vergu&amp;author=NM+Ferguson&amp;author=M+Lemaitre&amp;author=S+Cauchemez&amp;volume=167&amp;publication_year=2008&amp;pages=775-785&amp;pmid=18230677&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Lowen1">31. <span class="element-citation">Lowen AC, Steel J, Mubareka S, Carnero E, Garcia-Sastre A, et al.  Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. <span><span class="ref-journal">J Virol. </span>2009;<span class="ref-vol">83</span>:2803\xe2\x80\x932818.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2655561/">PMC free article</a>]</span> [<a href="/pubmed/19153237" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Blocking+interhost+transmission+of+influenza+virus+by+vaccination+in+the+guinea+pig+model.&amp;author=AC+Lowen&amp;author=J+Steel&amp;author=S+Mubareka&amp;author=E+Carnero&amp;author=A+Garcia-Sastre&amp;volume=83&amp;publication_year=2009&amp;pages=2803-2818&amp;pmid=19153237&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-terMeulen1">32. <span class="element-citation">ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, et al.  Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. <span><span class="ref-journal">Lancet. </span>2004;<span class="ref-vol">363</span>:2139\xe2\x80\x932141.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7112500/">PMC free article</a>]</span> [<a href="/pubmed/15220038" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Human+monoclonal+antibody+as+prophylaxis+for+SARS+coronavirus+infection+in+ferrets.&amp;author=J+ter+Meulen&amp;author=AB+Bakker&amp;author=EN+van+den+Brink&amp;author=GJ+Weverling&amp;author=BE+Martina&amp;volume=363&amp;publication_year=2004&amp;pages=2139-2141&amp;pmid=15220038&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Baras1">33. <span class="element-citation">Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, et al.  Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. <span><span class="ref-journal">PLoS ONE. </span>2008;<span class="ref-vol">3</span>:e1401.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2151135/">PMC free article</a>]</span> [<a href="/pubmed/18167560" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=Cross-protection+against+lethal+H5N1+challenge+in+ferrets+with+an+adjuvanted+pandemic+influenza+vaccine.&amp;author=B+Baras&amp;author=KJ+Stittelaar&amp;author=JH+Simon&amp;author=RJ+Thoolen&amp;author=SP+Mossman&amp;volume=3&amp;publication_year=2008&amp;pages=e1401&amp;pmid=18167560&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0009106-Rimmelzwaan1">34. <span class="element-citation">Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. <span><span class="ref-journal">J Virol Methods. </span>1998;<span class="ref-vol">74</span>:57\xe2\x80\x9366.</span> [<a href="/pubmed/9763129" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol+Methods&amp;title=Comparison+of+RNA+hybridization,+hemagglutination+assay,+titration+of+infectious+virus+and+immunofluorescence+as+methods+for+monitoring+influenza+virus+replication+in+vitro.&amp;author=GF+Rimmelzwaan&amp;author=M+Baars&amp;author=EC+Claas&amp;author=AD+Osterhaus&amp;volume=74&amp;publication_year=1998&amp;pages=57-66&amp;pmid=9763129&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2817000&amp;issue-id=184463&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">PLoS ONE</span> are provided here courtesy of <strong>Public Library of Science</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2817000/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2817000/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2817000/pdf/pone.0009106.pdf">PDF (305K)</a></li> | <li><a href="#" data-citationid="PMC2817000" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2817000%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2817000%2F&amp;text=New%20Class%20of%20Monoclonal%20Antibodies%20against%20Severe%20Influenza%3A%20Prophylactic%20and%20Therapeutic%20Efficacy%20in%20Ferrets"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2817000%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="20161706" data-aiid="2817000" data-aid="2817000" data-iid="184463" data-domainid="440" data-domain="plosone" data-accid="PMC2817000" data-md5="04bcb131737ce098360f5107fd9accc0"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T20:31:15-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc101&amp;ncbi_phid=8A1AD382E9A333C10000000008CB08CA&amp;ncbi_session=8A1AD382E9A4A521_2251SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2817000%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=plosone&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2817000/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1AD382E9A4A521_2251SID /projects/PMC/PMCViewer@4.46 ptpmc101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'